Promising Trials in DCIS

April 9, 2014
Henry M. Kuerer, MD, PhD, FACS

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses two ongoing trials that look promising for the treatment of patients with DCIS.

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses two ongoing trials that look promising for the treatment of patients with DCIS.

Clinical Pearls:

  • Patients with HER2/neu-positive DCIS who were being treated with trastuzumab showed a significant immune response to HER2/neu types of cancer cells, according to an MD Anderson study
  • A vaccine comprised of stimulated monocytes and immune cells from the patient has also shown promising results